Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.

Antimicrobial agents and chemotherapy - 1 Nov 2010

Poissy Julien, Aubry Alexandra, Fernandez Christine, Lott Marie-Catherine, Chauffour Aurelie, Jarlier Vincent, Farinotti Robert, Veziris Nicolas

Abstract excerpt

The prevalence of extensively drug-resistant tuberculosis (XDR-TB), defined as TB that is resistant to isoniazid, rifampin, fluoroquinolones, and aminoglycosides, is rising worldwide. The extent of Mycobacterium tuberculosis resistance to fluoroquinolones depends on the mutation in the DNA gyrase, the only target of fluoroquinolones. The MIC of moxifloxacin, the most active fluoroquinolone against M....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Aza Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Gyrase

Share to Fluoroquinolones

Share to Moxifloxacin

Share to Ofloxacin

Share to Quinolines

Share to Tuberculosis, Multidrug-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 20805388
DOI: 10.1128/AAC.00968-10
PMCID: PMC2976119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.PMID 20805388Read ↗

In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.Semantic proximity Read ↗

Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.Semantic proximity Read ↗

Drug testing in mouse models of tuberculosis and nontuberculous mycobacterial infections.Semantic proximity Read ↗

Efficacy of macozinone in mice with genetically diverse susceptibility to Mycobacterium tuberculosis infection.Semantic proximity Read ↗

Therapy for Mycobacterium kansasii Infection: Beyond 2018Semantic proximity Read ↗

Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.Semantic proximity Read ↗

Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.Semantic proximity Read ↗

Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice modelsSemantic proximity Read ↗

Mutations in <i>fbiD (Rv2983)</i> as a novel determinant of resistance to pretomanid and delamanid in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Improving treatment outcome assessment in a mouse tuberculosis model.Semantic proximity Read ↗

The C3HeB/FeJ Kramnik mouse as a model to investigate the efficacy of therapeutic tuberculosis interventionsSemantic proximity Read ↗

Next Generation TB Drug Combinations from the Pan-TB Consortium: Combination Efficacy and Contributions of Individual Agents, Evaluated in a BALB/c Mouse TB ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.